ATE545651T1 - Vektoren zur expression von hml-2-polypeptiden - Google Patents

Vektoren zur expression von hml-2-polypeptiden

Info

Publication number
ATE545651T1
ATE545651T1 AT03741966T AT03741966T ATE545651T1 AT E545651 T1 ATE545651 T1 AT E545651T1 AT 03741966 T AT03741966 T AT 03741966T AT 03741966 T AT03741966 T AT 03741966T AT E545651 T1 ATE545651 T1 AT E545651T1
Authority
AT
Austria
Prior art keywords
hml
promoter
polypeptides
nucleic acid
sequence encoding
Prior art date
Application number
AT03741966T
Other languages
English (en)
Inventor
Stephen Hardy
John Donnelly
Megede Jan Zur
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Priority claimed from PCT/US2003/018666 external-priority patent/WO2003106634A2/en
Application granted granted Critical
Publication of ATE545651T1 publication Critical patent/ATE545651T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03741966T 2002-06-13 2003-06-13 Vektoren zur expression von hml-2-polypeptiden ATE545651T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38883102P 2002-06-13 2002-06-13
US47218903P 2003-05-20 2003-05-20
PCT/US2003/018666 WO2003106634A2 (en) 2002-06-13 2003-06-13 Vectors for expression of hml-2 polypeptides

Publications (1)

Publication Number Publication Date
ATE545651T1 true ATE545651T1 (de) 2012-03-15

Family

ID=34221115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03741966T ATE545651T1 (de) 2002-06-13 2003-06-13 Vektoren zur expression von hml-2-polypeptiden

Country Status (6)

Country Link
US (1) US8518694B2 (de)
EP (2) EP1532161B1 (de)
JP (3) JP2005535308A (de)
AT (1) ATE545651T1 (de)
AU (1) AU2003276679A1 (de)
CA (1) CA2489292A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535765A (ja) * 2000-12-07 2004-12-02 カイロン コーポレイション 前立腺癌においてアップレギュレートされた内因性レトロウイルス
US20060275747A1 (en) * 2001-12-07 2006-12-07 Hardy Stephen F Endogenous retrovirus up-regulated in prostate cancer
EP3846839A1 (de) * 2018-09-06 2021-07-14 Centre Léon Bérard Von herv-k abgeleitete antigene als gemeinsame tumorantigene für krebsimpfstoffe
JP7344300B2 (ja) 2018-09-18 2023-09-13 ブイエヌブイ ニューコ インク． Ａｒｃベースのカプシドおよびその使用
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1660401A (en) 1926-05-10 1928-02-28 Strauss Ets Lighter
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE240401T1 (de) 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
EP0487587A1 (de) 1989-08-18 1992-06-03 Chiron Corporation Rekombinante retroviren um vektorkonstruktionen an zielzellen zu liefern
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5252296A (en) 1990-05-15 1993-10-12 Chiron Corporation Method and apparatus for biopolymer synthesis
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
RU2142467C1 (ru) 1990-07-27 1999-12-10 Чирон Диагностикс Корпорейшн Полинуклеотиды, способ их получения, гибридизационный анализ нуклеиновой кислоты
ES2144414T3 (es) 1990-12-20 2000-06-16 Arch Dev Corp The University O Control de la expresion de un gen por medio de una radiacion ionizante.
ATE338134T1 (de) 1991-02-08 2006-09-15 Aventis Pharma Sa Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen
EP0509112B1 (de) 1991-04-16 1997-01-22 Siemens Aktiengesellschaft Ausgangpufferverstärker
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
CA2128616A1 (en) 1992-01-23 1993-08-05 Gary H. Rhodes Ex vivo gene transfer
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US5650277A (en) 1992-07-02 1997-07-22 Diagenetics Ltd. Method of determining the presence and quantifying the number of di- and trinucleotide repeats
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
EP0689454B2 (de) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
ATE227979T1 (de) 1993-04-22 2002-12-15 Skyepharma Inc Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
EP0694070B1 (de) 1993-09-15 2002-04-10 Chiron Corporation Rekombinanter alphavirus vektor
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SK283703B6 (sk) 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
DK0729351T3 (da) 1993-11-16 2000-10-16 Skyepharma Inc Vesikler med reguleret afgivelse af aktivstoffer
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6974666B1 (en) 1994-10-21 2005-12-13 Appymetric, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP0822830B1 (de) 1995-04-27 2008-04-02 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5858723A (en) 1995-12-05 1999-01-12 Behringwerke Aktiengesellschaft Polypeptides and antibodies for diagnosing and treating seminoma
WO1997025431A1 (en) 1996-01-10 1997-07-17 Corixa Corporation Compositions and methods for the treatment and diagnosis of cancer
JP2002515738A (ja) 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド 核酸分析法
US6228575B1 (en) 1996-02-08 2001-05-08 Affymetrix, Inc. Chip-based species identification and phenotypic characterization of microorganisms
US6458530B1 (en) 1996-04-04 2002-10-01 Affymetrix Inc. Selecting tag nucleic acids
DE69739286D1 (de) 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
US5916872A (en) 1996-07-24 1999-06-29 Intrabiotics Pharmaceuticals, Inc. Cyclic peptides having broad spectrum antimicrobial activity
EP2305027B1 (de) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgene Saügertiere, die menschlichen Ig-loci einschließlich mehrere VH und Vkappa Regionen enthalten, und davon erhaltene Antikörper
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU5340399A (en) 1998-08-10 2000-03-06 Incyte Pharmaceuticals, Inc. Proteases and associated proteins
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
ATE481108T1 (de) 1999-02-26 2010-10-15 Novartis Vaccines & Diagnostic Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
US6753314B1 (en) 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
JP2003518364A (ja) 1999-05-28 2003-06-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用
EP1074617A3 (de) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers für Synthese von ganzen-Länge cDNS und deren Anwendung
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
WO2001042467A2 (en) 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
NO314091B1 (no) 2000-01-12 2003-01-27 Biotec Pharmacon Asa Varmelabil uracil-DNA-glykosylase, DNA-sekvens som koder for enzymet, mikroorganisme som inneholder DNA-sekvensen, samt anvendelse av enzymet
WO2001055309A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
WO2001060860A2 (en) 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP2004535765A (ja) * 2000-12-07 2004-12-02 カイロン コーポレイション 前立腺癌においてアップレギュレートされた内因性レトロウイルス
JP4646315B2 (ja) * 2001-12-07 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 前立腺癌においてアップレギュレートされた内因性レトロウイルス
WO2003050258A2 (en) * 2001-12-07 2003-06-19 Chiron Corporation Endogenous retrovirus polypeptides linked to oncogenic transformation
WO2004069174A2 (en) * 2003-01-31 2004-08-19 Slil Biomedical Corporation Monitoring and treatment of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
JP2013143953A (ja) 2013-07-25
EP1532161A2 (de) 2005-05-25
JP2009268478A (ja) 2009-11-19
JP2005535308A (ja) 2005-11-24
CA2489292A1 (en) 2003-12-24
US20100086565A1 (en) 2010-04-08
EP2302039A1 (de) 2011-03-30
US8518694B2 (en) 2013-08-27
EP1532161B1 (de) 2012-02-15
AU2003276679A1 (en) 2003-12-31
EP1532161A4 (de) 2006-05-24
AU2003276679A8 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
ATE421537T1 (de) Erkennungsmoleküle zur behandlung und detektion von tumoren
NO20024475L (no) Produksjon av rekombinante blodkoagulasjonsfaktorer i humane cellelinjer
DK1626058T3 (da) Sammensætninger og fremgangsmåder til diagnosticering af tumor
JP2020510426A5 (de)
WO2024207617A1 (zh) 重编程因子抗衰老mRNA组合物、制备方法及应用
DE60120500D1 (de) In Knorpelgeweben stark exprimiertes Gen
ATE320484T1 (de) Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung
MX2022011806A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher.
ATE420191T1 (de) Promotoren zur expression im modifizierten vacciniavirus ankara
ATE545651T1 (de) Vektoren zur expression von hml-2-polypeptiden
ATE461283T1 (de) Neue vollständige genomische rna des japanenzephalitis-virus, infektiöse jev cdna daraus und deren verwendung
DE60129069D1 (de) Hepatitis B Virus Vektoren für Gentherapie
ATE408029T1 (de) Verfahren zur herstellung und identifizierung löslicher proteindomänen
Sadikoglou et al. Comparative analysis of internal ribosomal entry sites as molecular tools for bicistronic expression
ATE383373T1 (de) Verwendung von cd34 oder eines davon abgeleiteten polypeptids als oberflächenmarker für gentransfer
WO2005005612A3 (en) Tag-1 and tag-2 proteins and uses thereof
CN103114104A (zh) 一种抑癌肽基因重组及其抗肿瘤应用
WO2002101069A3 (en) Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
DE60310708D1 (de) In vivo stabilsierung von plasmiden
JP6830651B2 (ja) ペプチド、ポリヌクレオチド、ベクター、形質転換体、ＮＦκＢ阻害剤、及びＮＦκＢ亢進性疾患の治療剤
JP2005518198A5 (de)
MXPA03010739A (es) Moleculas de marcador endotelial tumoral 7-alfa y uso de las mismas.
EP1201680A3 (de) Tumorsuppressor-Polypeptide aus CHC1-L (chromosome condensation 1-like)
WO2002024750A3 (en) Human kidney tumor overexpressed membrane protein 1
JP3425620B2 (ja) プロテアソーム分解に抵抗性を示す新規ｐ２７Ｋｉｐ１分子種の核酸及びアミノ酸配列と同蛋白質の発現ベクター及び発現細胞